Azadeh Abravan1,2, Hanne Astrid Eide3,4, Ayca Muftuler Løndalen5, Åslaug Helland3,4,6, Eirik Malinen7,8. 1. Department of Medical Physics, Oslo University Hospital, PO Box 4953, Nydalen, N-0424, Oslo, Norway. azadeh.abravan@fys.uio.no. 2. Department of Physics, University of Oslo, Oslo, Norway. azadeh.abravan@fys.uio.no. 3. Department of Oncology, Oslo University Hospital, Oslo, Norway. 4. Institute for Cancer Research, Oslo University Hospital, Oslo, Norway. 5. Department of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway. 6. Institute of Clinical Medicine, University of Oslo, Oslo, Norway. 7. Department of Medical Physics, Oslo University Hospital, PO Box 4953, Nydalen, N-0424, Oslo, Norway. 8. Department of Physics, University of Oslo, Oslo, Norway.
Abstract
PURPOSE: To map functional bone marrow (BM) by 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) positron emission tomography (PET) in the vertebral column of lung cancer patients prior to, during, and after treatment. Moreover, to identify radiation- and erlotinib-induced changes in the BM. PROCEDURES: Twenty-six patients with advanced non-small cell lung cancer, receiving radiotherapy (RT) alone or concomitantly with erlotinib, were examined by [18F]FDG PET before, during, and after treatment. A total of 61 [18F]FDG PET scans were analyzed. Vertebral column BM [18F]FDG standardized uptake value normalized to the liver (SUVBMLR) was used as uptake measure. Wilcoxon signed-rank test was used to assess changes in BM uptake of [18F]FDG between sessions. Effects of erlotinib on the BM activity during and after treatment were assessed using Mann-Whitney U test. RESULTS: A homogeneous uptake of [18F]FDG was observed within the vertebral column prior to treatment. Mean SUVBMLR (± S.E.M) in the body of thoracic vertebrae receiving a total RT dose of 10 Gy or higher was 0.64 ± 0.01, 0.56 ± 0.01, and 0.59 ± 0.01 at pre-, mid-, and post-therapy, respectively. A significant reduction in the mean SUVBMLR was observed from pre- to both mid- and post-therapy (p < 0.05). Mean SUVBMLR was significantly higher at post-therapy compared to mid-therapy for patients receiving erlotinib in addition to RT (p < 0.05). CONCLUSIONS: RT reduces BM [18F]FDG uptake in the vertebral column, especially in the high-dose region. Concomitant erlotinib may stimulate a recovery in BM [18F]FDG uptake from mid- to post-therapy. TRIAL REGISTRATION: NCT02714530. Registered 10 September 2015.
PURPOSE: To map functional bone marrow (BM) by 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) positron emission tomography (PET) in the vertebral column of lung cancerpatients prior to, during, and after treatment. Moreover, to identify radiation- and erlotinib-induced changes in the BM. PROCEDURES: Twenty-six patients with advanced non-small cell lung cancer, receiving radiotherapy (RT) alone or concomitantly with erlotinib, were examined by [18F]FDG PET before, during, and after treatment. A total of 61 [18F]FDG PET scans were analyzed. Vertebral column BM [18F]FDG standardized uptake value normalized to the liver (SUVBMLR) was used as uptake measure. Wilcoxon signed-rank test was used to assess changes in BM uptake of [18F]FDG between sessions. Effects of erlotinib on the BM activity during and after treatment were assessed using Mann-Whitney U test. RESULTS: A homogeneous uptake of [18F]FDG was observed within the vertebral column prior to treatment. Mean SUVBMLR (± S.E.M) in the body of thoracic vertebrae receiving a total RT dose of 10 Gy or higher was 0.64 ± 0.01, 0.56 ± 0.01, and 0.59 ± 0.01 at pre-, mid-, and post-therapy, respectively. A significant reduction in the mean SUVBMLR was observed from pre- to both mid- and post-therapy (p < 0.05). Mean SUVBMLR was significantly higher at post-therapy compared to mid-therapy for patients receiving erlotinib in addition to RT (p < 0.05). CONCLUSIONS: RT reduces BM [18F]FDG uptake in the vertebral column, especially in the high-dose region. Concomitant erlotinib may stimulate a recovery in BM [18F]FDG uptake from mid- to post-therapy. TRIAL REGISTRATION: NCT02714530. Registered 10 September 2015.
Entities:
Keywords:
Bone marrow; Erlotinib; FDG-PET; NSCLC; Thoracic radiotherapy; Vertebral column
Authors: Brent S Rose; Yun Liang; Steven K Lau; Lindsay G Jensen; Catheryn M Yashar; Carl K Hoh; Loren K Mell Journal: Int J Radiat Oncol Biol Phys Date: 2012-01-21 Impact factor: 7.038
Authors: Marnie A Ryan; Kalpana J Nattamai; Ellen Xing; David Schleimer; Deidre Daria; Amitava Sengupta; Anja Köhler; Wei Liu; Matthias Gunzer; Michael Jansen; Nancy Ratner; Timothy D Le Cras; Amanda Waterstrat; Gary Van Zant; Jose A Cancelas; Yi Zheng; Hartmut Geiger Journal: Nat Med Date: 2010-09-26 Impact factor: 53.440
Authors: Yun Liang; Mark Bydder; Catheryn M Yashar; Brent S Rose; Mariel Cornell; Carl K Hoh; Joshua D Lawson; John Einck; Cheryl Saenz; Paul Fanta; Arno J Mundt; Graeme M Bydder; Loren K Mell Journal: Int J Radiat Oncol Biol Phys Date: 2012-06-09 Impact factor: 7.038
Authors: Angela van Baardwijk; Geert Bosmans; Liesbeth Boersma; Stofferinus Wanders; André Dekker; Anne Marie C Dingemans; Gerben Bootsma; Wiel Geraedts; Cordula Pitz; Jean Simons; Philippe Lambin; Dirk De Ruysscher Journal: Int J Radiat Oncol Biol Phys Date: 2008-02-06 Impact factor: 7.038